INSERM, U1052, Cancer Research Center of Lyon (CRCL), Université de Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard, Lyon, France.
INSERM, U1052, Cancer Research Center of Lyon (CRCL), Université de Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard, Lyon, France; Department of Translational Research and Innovation and Department of Medicine, Centre Léon Bérard, Lyon, France.
J Hepatol. 2019 Oct;71(4):763-772. doi: 10.1016/j.jhep.2019.05.031. Epub 2019 Jun 18.
BACKGROUND & AIMS: Low levels of toll-like receptor 3 (TLR3) in patients with hepatocellular carcinoma (HCC) are associated with poor prognosis, primarily owing to the loss of inflammatory signaling and subsequent lack of immune cell recruitment to the liver. Herein, we explore the role of TLR3-triggered apoptosis in HCC cells.
Quantitative reverse transcription PCR, western blotting, immunohistochemistry and comparative genomic hybridization were used to analyze human and mouse HCC cell lines, as well as surgically resected primary human HCCs, and to study the impact of TLR3 expression on patient outcomes. Functional analyses were performed in HCC cells, following the restoration of TLR3 by lentiviral transduction. The role of TLR3-triggered apoptosis in HCC was analyzed in vivo in a transgenic mouse model of HCC.
Lower expression of TLR3 in tumor compared to non-tumor matched tissue was observed at both mRNA and protein levels in primary HCC, and was predictive of shorter recurrence-free survival after surgical resection in both univariate (hazard ratio [HR] 1.79; 95% CI 1.04-3.06; p = 0.03) and multivariate analyses (HR 1.73; CI 1.01-2.97; p = 0.04). Immunohistochemistry confirmed frequent downregulation of TLR3 in human and mouse primary HCC cells. None of the 6 human HCC cell lines analyzed expressed TLR3, and ectopic expression of TLR3 following lentiviral transduction not only restored the inflammatory response but also sensitized cells to TLR3-triggered apoptosis. Lastly, in the transgenic mouse model of HCC, absence of TLR3 expression was accompanied by a lower rate of preneoplastic hepatocyte apoptosis and accelerated hepatocarcinogenesis without altering the tumor immune infiltrate.
Downregulation of TLR3 protects transforming hepatocytes from direct TLR3-triggered apoptosis, thereby contributing to hepatocarcinogenesis and poor patient outcome.
Hepatocellular carcinoma (HCC) is a heterogeneous disease associated with a poor prognosis. In patients with HCC, TLR3 downregulation is associated with reduced survival. Herein, we show that the absence of TLR3 is associated with a lower rate of apoptosis, and subsequently more rapid hepatocarcinogenesis, without any change to the immune infiltrate in the liver. Therefore, the poor prognosis associated with low TLR3 expression in HCC is likely linked to tumors ability to escape apoptosis. TLR3 may become a promising therapeutic target in TLR3-positive HCC.
在肝细胞癌(HCC)患者中,Toll 样受体 3(TLR3)水平较低与预后不良有关,主要是由于炎症信号丢失以及随后免疫细胞无法招募到肝脏。在此,我们研究 TLR3 触发的细胞凋亡在 HCC 细胞中的作用。
采用定量逆转录 PCR、Western blot、免疫组化和比较基因组杂交分析人源和鼠源 HCC 细胞系以及手术切除的原发性人 HCC,并研究 TLR3 表达对患者结局的影响。通过慢病毒转导恢复 TLR3 后,在 HCC 细胞中进行功能分析。在 HCC 的转基因小鼠模型中,分析 TLR3 触发的细胞凋亡在 HCC 中的作用。
在原发性 HCC 中,肿瘤组织中 TLR3 的 mRNA 和蛋白水平均低于配对的非肿瘤组织,且在手术切除后的无复发生存率中具有预测作用(单因素 HR 1.79;95%CI 1.04-3.06;p=0.03)和多因素分析(HR 1.73;CI 1.01-2.97;p=0.04)。免疫组化证实人源和鼠源原发性 HCC 细胞中 TLR3 频繁下调。分析的 6 个人 HCC 细胞系均不表达 TLR3,而慢病毒转导后 TLR3 的异位表达不仅恢复了炎症反应,而且还使细胞对 TLR3 触发的凋亡敏感。最后,在 HCC 的转基因小鼠模型中,TLR3 表达缺失伴随着较低的癌前肝细胞凋亡率和加速的肝癌发生,而不改变肿瘤免疫浸润。
TLR3 下调可保护转化的肝细胞免受 TLR3 触发的直接凋亡,从而促进肝癌发生和患者预后不良。
肝细胞癌(HCC)是一种异质性疾病,预后不良。在 HCC 患者中,TLR3 下调与生存率降低有关。在此,我们发现 TLR3 缺失与较低的凋亡率相关,随后肝癌发生更快,而肝脏中的免疫浸润无任何变化。因此,HCC 中 TLR3 表达较低与预后不良相关可能与肿瘤逃避凋亡的能力有关。TLR3 可能成为 TLR3 阳性 HCC 的有前途的治疗靶点。